Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Total revenue | 7,670 | 19,223 | 14,143 | 33,968 |
| Operating costs and expenses | ||||
| Cost of revenue | 11,491 | 20,161 | 23,981 | 41,990 |
| Research and development | 89,614 | 128,636 | 177,510 | 258,269 |
| General and administrative | 41,533 | 46,653 | 76,124 | 101,304 |
| Total operating costs and expenses | 142,638 | 195,450 | 277,615 | 401,563 |
| Loss from operations | (134,968) | (176,227) | (263,472) | (367,595) |
| Other income (loss), net | 3,962 | 4,330 | 10,359 | (6,947) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s R&D?
- Recursion Pharmaceuticals, Inc. (RXRX) reported R&D of $89.61M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s R&D changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s R&D decreased by 30.3% year-over-year, from $128.64M to $89.61M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s R&D?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s R&D has grown at a 36.9% compound annual growth rate (CAGR), from $135.27M to $475.27M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Recursion Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude